UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 11, 2017
OPIANT PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Nevada | | 000-55330 | | 46-4744124 |
(State or other jurisdiction of
incorporation) | | (Commission File Number | | (IRS Employer
Identification No.) |
401 Wilshire Blvd., 12th Floor Santa Monica, CA | | 90401 |
(Address of Principal Executive Offices) | | (Zip Cope) |
Registrant’s telephone number, including area code
| |
| (Former name or former address if changed since last report,) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On January 11, 2017, Opiant Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its 2017 corporate and clinical goals which include, but are not limited to: (i) initiating a Phase 2 study in Bulimia Nervosa; (ii) continuing to provide ongoing development and intellectual property support for Adapt Pharma Limited, the Company’s NARCAN® Nasal Spray commercialization partner; (iii) hiring a Chief Scientific Officer; (iv) completing an uplisting to a major stock exchange; and (v) reincorporating from Nevada to Delaware.
The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.
| Item 9.01 | Financial Statements and Exhibits. |
| Exhibit No. | Description |
| | |
| 99.1 | Opiant Pharmaceuticals, Inc. Press Release, dated January 11, 2017. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | Opiant Pharmaceuticals, Inc. |
| | | |
| Date: January 18, 2017 | By: | /s/Dr. Roger Crystal |
| | | Name: Dr. Roger Crystal |
| | | Title: President and Chief Executive Officer |
